Screener
Haemonetics HAE MedSurg — Net revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
| Line item | Three Months Ended / June 27, 2026 | June 28, 2025 |
|---|---|---|
| Plasma | $155,524 | $145,074 |
| Other | 35,794 | 36,662 |
| Apheresis net revenues | $191,318 | $181,736 |
| MedSurg | ||
| Interventional Technologies | $59,942 | $58,483 |
| Blood Management Technologies | 88,120 | 81,175 |
| MedSurg net revenues | $148,062 | $139,658 |
| Total net revenues | $339,380 | $321,394 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Haemonetics's medsurg — net revenues?
- Haemonetics (HAE) reported medsurg — net revenues of $148.06M in Q2 2026.
- What does medsurg — net revenues mean?
- This metric represents the total revenue generated from the sale of medical and surgical products and services within the specific business segment. It serves as a primary indicator of the segment's market demand, pricing power, and overall commercial success. Investors use this to evaluate the segment's contribution to the company's top-line growth and its competitive positioning in the healthcare market.
Ask your AI about Haemonetics's medsurg — net revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude